ReviewCNS drugs2014
Pregabalin: a review of its use in adults with generalized anxiety disorder.
Review in CNS drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Systematic review: The relationship between gabapentinoids, etizolam, and drug related deaths in Scotland.PloS one · 2024Pooled it
- Continuous-Flow Synthesis of Antiepileptic Drugs: Process Intensification, Sustainability Metrics, and Scalable Manufacturing.ACS omega · 2026Review
- Golden window of intervention in PTSD: a synthesis of preclinical evidence.Psychopharmacology · 2026Review
- Mendelian Randomization Uncovers Potential Repurposable Medications for Neuropsychiatric Disorders.Current neuropharmacology · 2026Article
- Once-Nightly Pregabalin for Co-Occurring Nightmares, Poor Sleep, and Headaches: A Case Series.Nature and science of sleep · 2026Article
- Epinephrine, Pregabalin, and Crizotinib as Three Medicines with Polish Implications over Three Last Centuries and in View of Three Different Drug Discovery Approaches.Biomedicines · 2024Review
- Pregabalin-Induced Bullous Pemphigoid: A Case Report of a Rare Drug-Triggered Autoimmune Skin Disorder.Cureus · 2024Article
- Exosomal TNF-α mediates voltage-gated Na+ channel 1.6 overexpression and contributes to brain tumor-induced neuronal hyperexcitability.The Journal of clinical investigation · 2024Article
- Evaluation of the teratogenic effects of pregabalin usage during pregnancy: A multicenter case-control study.Northern clinics of Istanbul · 2024Article
- Pharmacokinetic properties of a new sustained-release pregabalin tablet in subjects with reduced renal function.Translational and clinical pharmacology · 2023Article
- Depression and anxiety in glioma patients.Neuro-oncology practice · 2023Review
- Misuse of Pregabalin: a qualitative study from a patient's perspective.BMC public health · 2023Article
- Pregabalin Alleviates Anxiety and Fear in Cats during Transportation and Veterinary Visits-A Clinical Field Study.Animals : an open access journal from MDPI · 2023Article
- Pharmacokinetics of single and repeated oral doses of pregabalin oral solution formulation in cats.Journal of veterinary pharmacology and therapeutics · 2022Article
- A single injection of pregabalin induces short- and long-term beneficial effects on fear memory and anxiety-like behavior in rats with experimental type-1 diabetes mellitus.Metabolic brain disease · 2022Article
- The teratogenic effect of pregabalin on heart, liver and kidney in rats: a light microscopic, electron microscopic and immunohistochemical study.BMC pharmacology & toxicology · 2022Article
- Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials.Frontiers in pharmacology · 2022Review
- The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2021Article
- Continuous flow asymmetric synthesis of chiral active pharmaceutical ingredients and their advanced intermediates.Green chemistry : an international journal and green chemistry resource : GC · 2021Review
- Perioperative Anxiolytic and Analgesic Effects of Pregabalin in Vitreo-Retinal Surgery: A Randomized, Double-blind Study.Anesthesiology and pain medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregabalin (Lyrica(®)), a well established anxiolytic agent, has been approved in the EU for the treatment of generalized anxiety disorder (GAD) in adults. It has a distinct mechanism of action relative to other anti-anxiety agents (α2δ binding at presynaptic voltage dependent calcium channels leading to inhibition of excitatory neurotransmission), a rapid onset of effect (typically ≤1 week) and broad spectrum activity against both the psychic and somatic symptoms of GAD. In long-term studies, pregabalin maintained improvements in anxiety symptoms that occurred in response to short-term treatment and delayed the time to relapse of GAD compared with placebo. Common comorbidities of GAD, such as insomnia, gastrointestinal symptoms and subsyndromal depression, have no effect on the anxiolytic efficacy of, and moreover are specifically improved by, pregabalin. Treatment with pregabalin is generally well tolerated; the drug has an adverse event profile that includes dizziness, somnolence and weight gain. The potential for abuse of pregabalin is low; the risk of withdrawal symptoms is generally low when the drug is discontinued gradually (over 1 week). Alongside selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), pregabalin is considered a first-line agent for the long-term treatment of GAD by the World Federation of Societies of Biological Psychiatry. It should be stressed, however, that definitive head-to-head studies comparing pregabalin with SSRI/SNRIs, including in patients with GAD and co-morbid major depressive disorder, are currently lacking. Recently, a study of SSRI/SNRI augmentation with pregabalin yielded positive results, while another study of switching from long-term benzodiazepine therapy to pregabalin was inconclusive; further investigations on these topics are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.